There are separate treatment pathways for people with a category A and course B CPS and for individuals with a class C CPS. Furthermore, the authors offer an algorithmic approach to these agents from the transplant populace, focusing on initially line usage of glucagon-like peptide 1 (GLP-1) agonists because https://glp-1-reviews14703.full-design.com/glp-1-tirzepatide-an-overview-79163920